RXRX
Company Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 74.68M | 58.84M | 43.88M | 39.68M | 10.00M | 3.41M | 1.71M |
| Net Income | (644.76M) | (463.66M) | (328.07M) | (239.48M) | (186.48M) | (87.01M) | (62.52M) |
| EPS | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Free Cash Flow | (378.28M) | (372.87M) | (300.33M) | (120.88M) | (198.41M) | (52.13M) | (60.95M) |
| FCF / Share | -0.85 | -1.36 | -1.44 | -0.69 | -1.17 | -0.31 | -0.37 |
| Operating CF | (371.81M) | (359.17M) | (287.78M) | (83.52M) | (158.61M) | (45.40M) | (57.04M) |
| Total Assets | 1.47B | 1.45B | 653.70M | 701.29M | 610.35M | 298.58M | 101.43M |
| Total Debt | 77.97M | 108.49M | 50.67M | 51.01M | 11.48M | 15.66M | 16.17M |
| Cash & Equiv | 743.29M | 594.35M | 391.56M | 549.91M | 285.12M | 262.13M | 69.88M |
| Book Value | 1.13B | 1.03B | 463.44M | 485.81M | 542.94M | (206.29M) | (124.27M) |
| Return on Equity | -0.57 | -0.45 | -0.71 | -0.49 | -0.34 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.47M | 35.54M | 5.17M | 19.10M | 14.74M | 4.51M | 26.08M | 14.40M | 13.49M | 10.62M | 10.10M | 11.02M |
| Net Income | (117.50M) | (108.12M) | (162.25M) | (171.90M) | (202.49M) | (178.91M) | (95.67M) | (97.54M) | (91.37M) | (93.00M) | (93.02M) | (76.73M) |
| EPS | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 | -0.39 | -0.40 | -0.43 | -0.38 |
| Free Cash Flow | (81.36M) | (47.32M) | (117.60M) | (79.57M) | (133.79M) | (117.08M) | (63.79M) | (86.40M) | (108.95M) | (76.49M) | (73.75M) | (71.44M) |
| FCF / Share | -0.15 | -0.09 | -0.26 | -0.19 | -0.33 | -0.35 | -0.23 | -0.36 | -0.46 | -0.33 | -0.34 | -0.35 |
| Operating CF | (81.10M) | (46.07M) | (117.36M) | (76.42M) | (131.96M) | (115.43M) | (59.23M) | (82.22M) | (102.30M) | (74.08M) | (72.92M) | (67.47M) |
| Total Assets | 1.34B | 1.47B | 1.40B | 1.30B | 1.31B | 1.45B | 726.50M | 775.86M | 557.85M | 653.70M | 630.83M | 666.70M |
| Total Debt | 72.38M | 77.97M | 82.37M | 88.08M | 92.91M | 108.49M | 90.62M | 89.88M | 50.97M | 50.67M | 51.48M | 52.90M |
| Cash & Equiv | 654.47M | 743.29M | 659.84M | 528.22M | 500.45M | 594.35M | 427.65M | 474.34M | 299.52M | 391.56M | 387.32M | 405.87M |
| Book Value | 1.02B | 1.13B | 1.05B | 919.15M | 933.95M | 1.03B | 524.56M | 584.45M | 401.15M | 463.44M | 437.97M | 468.96M |
| Return on Equity | -0.11 | -0.10 | -0.15 | -0.19 | -0.22 | -0.17 | -0.18 | -0.17 | -0.23 | -0.20 | -0.21 | -0.16 |
